Full-Time

Billing Data Entry Specialist

Posted on 5/15/2025

GeneDx

GeneDx

501-1,000 employees

Provides genetic testing for rare diseases

Compensation Overview

$31.25 - $33.65/hr

Mid, Senior

United States

Category
Data Entry
Clerical & Data Entry
Requirements
  • Strong knowledge with attention to detail
  • Proficiency in data entry
  • Understanding of medical billing and coding processes
  • 3-5 years of experience in billing data entry, preferably in healthcare or laboratory billing
  • Knowledge of industry regulations, including HIPAA
Responsibilities
  • Enter and verify patient demographic and billing information with a high level of accuracy.
  • Ensure interfaced patient data correctly transfers to the billing system and matches submitted entries.
  • Ensure correct payor is assigned to avoid reimbursement delays.
  • Identify and correct discrepancies in patient, provider, or insurance details before claim submission.
  • Maintain compliance with payor billing requirements and company policies.
  • Communicate with internal teams to resolve missing or inaccurate information.
  • Support timely and accurate claim submission by ensuring all billing data entry is complete and productivity metrics are maintained.
  • Ensure all data is kept confidential and adheres to industry standards for privacy and security.
  • Perform additional responsibilities as assigned while demonstrating company leadership attributes and supporting of the Mission and Values of the company.
Desired Qualifications
  • Experience with Xifin is a plus.
  • Strong organizational and communication skills.
  • Proficiency in Microsoft Office Suite (Excel, Word, Outlook, and Teams) and billing software.

GeneDx specializes in genetic testing to diagnose rare diseases by analyzing a patient's DNA for mutations linked to health conditions. The company collects DNA samples through cheek swabs, blood, or other specimens and sequences them to identify genetic variations. With over 300,000 clinical patient exomes sequenced, GeneDx provides rapid testing services, such as GenomeXpress and XomeDx Xpress, delivering results in as little as seven days. This quick turnaround is crucial for timely diagnosis and treatment, which can improve patient outcomes and reduce healthcare costs. Unlike many competitors, GeneDx focuses on personalized medicine and offers digital Patient Letters to help patients and families understand their genetic information. The company's goal is to lead in clinical genomics by providing accurate and efficient genetic testing services that support healthcare providers and enhance patient care.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Fabric Genomics enhances AI-powered genomic interpretation capabilities.
  • Integration with Epic Aura streamlines genomic testing and improves workflow efficiency.
  • Rapid whole genome sequencing in NICUs reduces diagnostic time and costs.

What critics are saying

  • Integration with Epic Aura may face technical and compatibility challenges.
  • Fabric Genomics acquisition could lead to integration and cultural challenges.
  • Rapid NICU genomic testing may face regulatory scrutiny over accuracy concerns.

What makes GeneDx unique

  • GeneDx excels in rapid and accurate genetic testing services.
  • The company integrates AI with genomic data for enhanced clinical insights.
  • GeneDx's Centrellis platform synthesizes clinical and genomic data effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

Employee Discounts

Voluntary benefits

Company News

Business Wire
May 8th, 2025
GeneDx Announces Completion of Fabric Genomics Acquisition

GeneDx (Nasdaq: WGS) today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation.

360Dx
Apr 16th, 2025
GeneDx to Acquire Fabric Genomics in Deal Potentially Worth $51M

NEW YORK - GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.

Hit Consultant
Apr 16th, 2025
Genedx Acquires Fabric Genomics For $33M, Expanding Access To Ai-Powered Genomic Interpretation

What You Should Know:– GeneDx, a company focused on improving health outcomes through genomic insights, has announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation.– The acquisition aims to position GeneDx at the forefront of the next phase of genomic medicine, characterized by decentralized testing with centralized intelligence. Following the closing of the acquisition, Fabric Genomics will initially operate independently while benefiting from GeneDx’s commercial support to accelerate its expansion.AI-Powered Genomic InterpretationThe acquisition is motivated by the increasing accessibility of DNA sequencing, which allows for the decoupling of interpretation services from physical laboratories. This decoupling is expected to provide greater flexibility in integrating genomic information into the workflows of healthcare providers and health systems, both in the U.S. and globally. Fabric Genomics’ platform is known for its ability to scale complex interpretation services and has been used to interpret challenging genetic disease cases for various large health systems, academic centers, and research partners.Through this acquisition, health systems will gain the option to use GeneDx’s centralized lab or conduct sequencing at their own facilities while leveraging GeneDx’s data and Fabric Genomics’ AI-powered interpretation platform. The companies believe that this model will lead to faster and earlier diagnoses of genetic diseases, improved patient outcomes, and reduced costs for healthcare systems.Expanding Market ReachThe acquisition will also enable GeneDx to expand its market reach into several key areas:NICU Genomic Testing: The companies aim to increase the use of rapid whole genome sequencing in NICUs, where it has the potential to reduce diagnostic time and costs and improve outcomes for infants.The companies aim to increase the use of rapid whole genome sequencing in NICUs, where it has the potential to reduce diagnostic time and costs and improve outcomes for infants

Stock Titan
Mar 18th, 2025
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today they have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025, and recognized as the No. 2 in the Biotech category.

The Chemical Data Company
Mar 13th, 2025
GeneDx to Present Key Research at 2025 ACMG Annual Meeting

GeneDx Showcases Groundbreaking Genomic Research at 2025 ACMG Annual Clinical Genetics Meeting